IN VIVO ANTIGENIC TARGETS OF T CELLS INDUCED BY ADENOVIRAL VECTORED VACCINES IN PATIENTS WITH CHRONIC HCV INFECTION

Documenti analoghi

• A THERAPEUTIC VACCINE FOR HCV BASED ON NOVEL, RARE, ADENOVIRAL VECTORS
  di: Kelly, C, et al.
  Pubblicazione: (2011)
• A highly immunogenic novel genetic vaccine against HCV
  di: Del Sorbo, M, et al.
  Pubblicazione: (2012)
• A human vaccine strategy based on chimpanzee adenoviral and MVA vectors that primes, boosts, and sustains functional HCV-specific T cell memory
  di: Swadling, L, et al.
  Pubblicazione: (2014)
• PHASE I TRIAL OF A HIGHLY IMMUNOGENIC T CELL VACCINE FOR HEPATITIS C VIRUS BASED ON NOVEL ADENOVIRAL VECTORS FROM RARE SEROTYPES
  di: Folgori, A, et al.
  Pubblicazione: (2009)
• Highly immunogenic virally vectored T-cell vaccines cannot overcome subversion of the T-cell response by HCV during chronic infection
  di: Swadling, L, et al.
  Pubblicazione: (2016)